Lupin Limited has officially announced its earnings call for the fourth quarter of fiscal year 2026, demonstrating its commitment to transparent stakeholder communication and regulatory compliance.

Earnings Call Schedule

The pharmaceutical company has scheduled its Q4 FY26 earnings call with specific timing and platform details to ensure broad stakeholder participation.

Regulatory Compliance

The earnings call announcement was made in strict adherence to Indian securities regulations. Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, the company has formally notified both major Indian stock exchanges about this quarterly disclosure event.

The notification was digitally signed by Amit Kumar Gupta, Company Secretary & Compliance Officer (ACS-15754), ensuring proper authorization and documentation of the regulatory filing.

Stakeholder Access

Lupin has provided multiple access methods for stakeholders to participate in the earnings call:

• Digital Registration: Online registration link provided for Zoom access
• QR Code Access: Quick response code available for mobile device registration
• Advance Registration: Participants advised to register before the scheduled time
• Early Join Recommendation: Stakeholders encouraged to join by 15:55 hrs IST

Exchange Notifications

The company has formally communicated the earnings call schedule to both primary Indian stock exchanges, maintaining transparency in its disclosure obligations.

This scheduled earnings call represents Lupin's ongoing commitment to maintaining regular communication with investors, analysts, and other stakeholders regarding its quarterly financial performance and business developments.

Lupin Limited has announced that its Board of Directors will convene on May 7, 2026, to review and approve the company's financial performance for the fourth quarter and full year ended March 31, 2026. The pharmaceutical company communicated this development to both the National Stock Exchange of India Limited and BSE Limited on April 22, 2026.

Board Meeting Agenda

The primary objectives of the scheduled board meeting include comprehensive review of the company's financial performance and strategic decisions for stakeholder returns.

Trading Window Restrictions

In accordance with regulatory compliance requirements, Lupin has implemented trading restrictions for designated personnel. The company has established a trading window closure period to ensure adherence to insider trading regulations.

Regulatory Compliance

The board meeting intimation follows Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window closure aligns with the company's Code of Conduct for Prohibition of Insider Trading and SEBI's Prohibition of Insider Trading Regulations, 2015.

The communication was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer, emphasizing the company's commitment to transparent corporate governance and regulatory adherence. Stakeholders and investors will receive the financial results and any dividend announcements following the board meeting conclusion.